Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy

Blood (2018) 132 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2018-99-113277

Published: 2018

Journal Articles

Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion — a Phase I Study (TOL-1)

Christian Morath, MD, Anita Schmitt, MD, Christian Kleist, PhD, Volker Daniel, MD, Gerhard Opelz, MD, Caner Süsal, MD, Florian Kälble, MD, Claudia Sommerer, MD, Lei Wang, MD, Angela Hückelhoven, PhD, Arianeb Mehrabi, MD, Uta Merle, MD, Luiza Pego da Silva, Carsten Müller-Tidow, MD, Martin Zeier, MD, Matthias Schaier, MD, Michael Schmitt, MD PhD, Peter Terness, MD

Blood (2018) 132 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2018-99-113386

Published: 2018

Journal Articles

Treg Downregulation Was Associated with Augmentation of T Cell Responses Against Immunogenic Antigens and Clinical Responses in Patients with Hematological Malignancies after Donor Lymphocyte Infusion (DLI)

Jochen Greiner, Marlies Götz, Michael Schmitt, MD PhD, Hartmut Döhner, MD, Markus Wiesneth, MD, Donald Bunjes, MD, Susanne Hofmann, MD

Blood (2018) 132 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2018-99-111783

Published: 2018

Journal Articles

Development of Potency Assays for Quality Assessment of an Advanced Therapy Medicinal Product: Mitomycin C-Induced Peripheral Blood Mononuclear Cell (MIC) Product

Ming NI, Lei Wang, MD, Christian Kleist, PhD, Peter Terness, MD, Gerhard Opelz, MD, Christian Morath, MD, Matthias Schaier, MD, Carsten Müller-Tidow, MD, Martin Zeier, MD, Michael Schmitt, MD PhD, Anita Schmitt, MD

Blood (2018) 132 (Supplement 1): 5689.

https://doi.org/10.1182/blood-2018-99-113337

Published: 2018

Journal Articles

Biomarkers for Clinical Response of Extracorporeal Photopheresis

Blood (2017) 130 (Supplement 1): 3264.

https://doi.org/10.1182/blood.V130.Suppl_1.3264.3264

Published: 2017

Journal Articles

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Sophia Stock, Jean-Marc Hoffmann, Lei Wang, MD, Wenjie Gong, Angela Hückelhoven, PhD, Brigitte Neuber, PhD, Maria-Luisa Schubert, MD, Ulrike Gern, Anita Schmitt, MD, Carsten Müller-Tidow, Peter Dreger, MD, Michael Schmitt, MD PhD, Leopold Sellner, MD

Blood (2017) 130 (Supplement 1): 3194.

https://doi.org/10.1182/blood.V130.Suppl_1.3194.3194

Published: 2017

Journal Articles

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Jochen Greiner, MD, Yoko Ono, Susanne Hofmann, Vanessa Schneider, Anita Schmitt, Lu Zhang, Elmar Mehring, Marlies Götz, Konstanze Döhner, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, MD, PhD

Blood (2011) 118 (21): 2569.

https://doi.org/10.1182/blood.V118.21.2569.2569

Published: 2011

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Krzysztof Giannopoulos, MD, PhD, Andreas Buhler, MD, PhD, Jinfei Chen, MD, PhD, Alexander Krober, MD, PhD, Malgorzata Kowal, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD, Jochen Greiner, MD, PhD, Hartmut Dohner, MD, PhD, Stephan Stilgenbauer, MD, PhD, Michael Schmitt, MD, PhD

Blood (2007) 110 (11): 2051.

https://doi.org/10.1182/blood.V110.11.2051.2051

Published: 2007

Journal Articles

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

Iwona Hus, MD, PhD, Michael Schmitt, MD, PhD, Jacek Tabarkiewicz, MD, PhD, Sebastian Radej, MD, Agnieszka Bojarska-Junak, PhD, Kamila Wojas, PhD, Anita Schmitt, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD

Blood (2007) 110 (11): 2052.

https://doi.org/10.1182/blood.V110.11.2052.2052

Published: 2007

Journal Articles

RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.

Krzysztof Giannopoulos, MD, PhD, Alexander Krober, MD, Anna Dmoszynska, Jacek Rolinski, Hartmut Dohner, Stephan Stilgenbauer, Michael Schmitt, MD PhD

Blood (2006) 108 (11): 2773.

https://doi.org/10.1182/blood.V108.11.2773.2773

Published: 2006

Journal Articles

High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.

Krzysztof Giannopoulos, MD, PhD, Michael Schmitt, MD PhD, Paulina Wlasiuk, MS C, Malgorzata Kowal, MD PhD, Monika Podhorecka, MD PhD, Jacek Rolinski, Anna Dmoszynska

Blood (2006) 108 (11): 2108.

https://doi.org/10.1182/blood.V108.11.2108.2108

Published: 2006

NARROW

No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy

Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion — a Phase I Study (TOL-1)

Treg Downregulation Was Associated with Augmentation of T Cell Responses Against Immunogenic Antigens and Clinical Responses in Patients with Hematological Malignancies after Donor Lymphocyte Infusion (DLI)

Development of Potency Assays for Quality Assessment of an Advanced Therapy Medicinal Product: Mitomycin C-Induced Peripheral Blood Mononuclear Cell (MIC) Product

Biomarkers for Clinical Response of Extracorporeal Photopheresis

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.

High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only